Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.81 USD | -0.15% | +6.41% | -2.71% |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
03-29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.71% | 19.18M | |
+33.25% | 699B | |
+25.40% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.83% | 236B | |
+4.91% | 198B | |
-10.10% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals to Sell EYSUVIS, INVELTYS to Alcon